Incidence rates have risen over the last 25 years, largely attributable to the introduction of prostate-specific antigen (PSA) testing [1], and prostate cancer is predicted to become the most commonly diagnosed cancer overall in the UK by 2030 [2]. This evidence concerns the gene KLK3 and prostate cancer.